March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Safety, Efficacy, And Treatment Patterns Of Ranibizumab Therapy For Neovascular Age-Related Macular Degeneration: The LUMINOUS Studies
Author Affiliations & Notes
  • Francesco Bandello
    Ophthalmology, University Vita Salute-Scientific Institute San Raffaele, Milan, Italy
  • Frank G. Holz
    Ophthalmology, University of Bonn, Bonn, Germany
  • Mark C. Gillies
    Ophthalmology, University of Sydney, Sydney, Australia
  • Adrian Koh
    Ophthalmology, Eye & Retina Surgeons Camden Medical Centre, Singapore, Singapore
  • Paul Mitchell
    Ophthalmology, University of Sydney, Sydney, Australia
  • LUMINOUS group
    Ophthalmology, University Vita Salute-Scientific Institute San Raffaele, Milan, Italy
  • Footnotes
    Commercial Relationships  Francesco Bandello, Novartis, Alcon, Alimera, Allergan, Bausch & Lomb, Bayer, Farmila-Thea, Genentech, Pfizer (C, R); Frank G. Holz, Allergan, Bayer, Genentech, Novartis, Pfizer (C, R); Mark C. Gillies, Novartis (C); Adrian Koh, Novartis (C); Paul Mitchell, Novartis, Pfizer (R), Novartis, Pfizer, Allergan, Solvay, Bayer (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2031. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Francesco Bandello, Frank G. Holz, Mark C. Gillies, Adrian Koh, Paul Mitchell, LUMINOUS group; Safety, Efficacy, And Treatment Patterns Of Ranibizumab Therapy For Neovascular Age-Related Macular Degeneration: The LUMINOUS Studies. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2031.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report on the LUMINOUS program including a retrospective pooled safety analysis of ranibizumab in European registries with neovascular age-related macular degeneration (nAMD) patients and the prospective study designed to assess long-term safety, efficacy, treatment patterns, and health-related quality of life outcomes in a large number of patients treated with ranibizumab in routine clinical practice across the world.

Methods: : Retrospective analysis: Four nAMD registries from Germany (n=3470), the Netherlands (n=243), Belgium (n=260), and Sweden (n=471) were completed and included in this retrospective analysis. The 12-month treatment exposure and 12-month incidences (% of patients) of targeted adverse events were assessed over all the registries. The study design of the prospective study (www.clinicaltrials.gov, NTC01318941) is presented.

Results: : Retrospective analysis: 4444 patients were included in the analysis. The mean number of ranibizumab injections ranged from 4.3 to 5.7 over 12 months. Over all registries, the targeted adverse events were associated with the following incidences during the 12-month follow-up period: 0.11% endophthalmitis, 0.07% intraocular inflammation, 0.23% cataract, 0.50% elevated intra-ocular pressure, 0.14% reduced retinal blood flow, 0.02% retinal tear, 0.02% retinal detachment, 0.61% retinal pigment epithelial tear, 0.18% vitreous hemorrhage, 0.18% hypersensitivity, 0.16% hypertension, 0.11% non-ocular hemorrhage, 0.11% myocardial infarction, 0.59% arterio-thromboembolic events, and 0.11% venous thromboembolic events. The prospective study is an ongoing global five year non-interventional, multicenter study in patients being treated with ranibizumab.

Conclusions: : The retrospective pooled analysis of European registries shows no new safety risks. A low number of ranibizumab injections in nAMD during the first year was noted. The ongoing LUMINOUS study further aids the characterization of both safety and efficacy profiles in addition to understanding treatment patterns and other outcomes achieved with ranibizumab in routine clinical practice.

Clinical Trial: : http://www.clinicaltrials.gov NCT01318941

Keywords: retina • age-related macular degeneration • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×